MedTrace Logo

Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation

NCT03234920 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-03-11

No results posted yet for this study

Summary

Sarcopenia is an independent predictor of morbidity and mortality in cirrhotic patient before and after liver transplantation. Beta-hydroxy-beta-methyl butyrate (HMB) is a leucine metabolite with potential efficacy in increasing protein synthesis, muscle mass and its functionality.

The aim of this randomized controlled study is to evaluate the effect of a nutritional supplementation with HMB after liver transplantation both on muscle mass and on muscle function.

Conditions

Interventions

DIETARY_SUPPLEMENT

BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)

1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily

OTHER

Placebo

The placebo will be 200 ml of fruit juice given twice daily

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Manuela Merli, Prof · University of Roma La Sapienza

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-25
Primary Completion
2018-09-15
Completion
2018-09-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03234920 on ClinicalTrials.gov